Comparing Brainsway (BWAY) & The Competition

Brainsway (NASDAQ:BWAY – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Brainsway to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings.

Earnings and Valuation

This table compares Brainsway and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Brainsway $52.22 million $7.57 million 16.96
Brainsway Competitors $1.89 billion $137.31 million 5.94

Brainsway’s competitors have higher revenue and earnings than Brainsway. Brainsway is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

30.1% of Brainsway shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Brainsway has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Brainsway’s competitors have a beta of 2.58, suggesting that their average share price is 158% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Brainsway and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainsway 0 2 4 0 2.67
Brainsway Competitors 4330 10559 18358 840 2.46

Brainsway currently has a consensus target price of $18.20, indicating a potential upside of 114.62%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.74%. Given Brainsway’s stronger consensus rating and higher possible upside, equities analysts plainly believe Brainsway is more favorable than its competitors.

Profitability

This table compares Brainsway and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Brainsway 15.54% 13.09% 8.50%
Brainsway Competitors -191.42% -197.86% -21.83%

Summary

Brainsway beats its competitors on 8 of the 13 factors compared.

About Brainsway

(Get Free Report)

BrainsWay Ltd. is an Israel-based medical technology company that develops and commercializes noninvasive treatments for mental health and neurological conditions. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields and specially designed H-Coils to stimulate brain regions associated with specific conditions. The company’s Deep TMS systems are used for conditions including major depressive disorder, obsessive-compulsive disorder and smoking addiction.

Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.